Literature DB >> 12067222

Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases?

Julie A Carson1, Anthony J Turner.   

Abstract

The steady-state level of amyloid beta-peptide (Abeta) represents a balance between its biosynthesis from the amyloid precursor protein (APP) through the action of the beta- and gamma-secretases and its catabolism by a variety of proteolytic enzymes. Recent attention has focused on members of the neprilysin (NEP) family of zinc metalloproteinases in amyloid metabolism. NEP itself degrades both Abeta(1-40) and Abeta(1-42) in vitro and in vivo, and this metabolism is prevented by NEP inhibitors. Other NEP family members, for example endothelin-converting enzyme, may contribute to amyloid catabolism and may also play a role in neuroprotection. Another metalloproteinase, insulysin (insulin-degrading enzyme) has also been advocated as an amyloid-degrading enzyme and may contribute more generally to metabolism of amyloid-forming peptides. Other candidate enzymes proposed include angiotensin-converting enzyme, some matrix metalloproteinases, plasmin and, indirectly, thimet oligopeptidase (endopeptidase-24.15). This review critically evaluates the evidence relating to proteinases implicated in amyloid catabolism. Therapeutic strategies aimed at promoting A,beta degradation may provide a novel approach to the therapy of Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12067222     DOI: 10.1046/j.1471-4159.2002.00855.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  68 in total

1.  Distinct ontogenic and regional expressions of newly identified Cajal-Retzius cell-specific genes during neocorticogenesis.

Authors:  Hiroshi Yamazaki; Mariko Sekiguchi; Masako Takamatsu; Yasuto Tanabe; Shigetada Nakanishi
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-27       Impact factor: 11.205

2.  Parkinson's and Alzheimer's diseases: protein aggregations and neuroprotection.

Authors:  Illana Gozes
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

3.  Gleevec increases levels of the amyloid precursor protein intracellular domain and of the amyloid-beta degrading enzyme neprilysin.

Authors:  Yvonne S Eisele; Matthias Baumann; Bert Klebl; Christina Nordhammer; Mathias Jucker; Ellen Kilger
Journal:  Mol Biol Cell       Date:  2007-07-11       Impact factor: 4.138

4.  Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy.

Authors:  Wesley Farris; Sonja G Schütz; John R Cirrito; Ganesh M Shankar; Xiaoyan Sun; Ana George; Malcolm A Leissring; Dominic M Walsh; Wei Qiao Qiu; David M Holtzman; Dennis J Selkoe
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

5.  Computer modeling and nanosecond simulation of the enzyme-substrate complex of the common lymphoblastic leukemia antigen (neprilysin) indicates shared residues at the primary specificity pocket (S1') with matrix metalloproteases.

Authors:  Sergio Manzetti
Journal:  J Mol Model       Date:  2003-08-29       Impact factor: 1.810

6.  Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo.

Authors:  Bonnie C Miller; Elizabeth A Eckman; Kumar Sambamurti; Nicole Dobbs; K Martin Chow; Christopher B Eckman; Louis B Hersh; Dwain L Thiele
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-05       Impact factor: 11.205

Review 7.  Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.

Authors:  Elizabeth Head; Ira T Lott; Donna M Wilcock; Cynthia A Lemere
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

8.  Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease.

Authors:  Nikolai D Belyaev; Natalia N Nalivaeva; Natalia Z Makova; Anthony J Turner
Journal:  EMBO Rep       Date:  2008-12-05       Impact factor: 8.807

9.  Gene-environment interaction research and transgenic mouse models of Alzheimer's disease.

Authors:  L Chouliaras; A S R Sierksma; G Kenis; J Prickaerts; M A M Lemmens; I Brasnjevic; E L van Donkelaar; P Martinez-Martinez; M Losen; M H De Baets; N Kholod; F van Leeuwen; P R Hof; J van Os; H W M Steinbusch; D L A van den Hove; B P F Rutten
Journal:  Int J Alzheimers Dis       Date:  2010-10-05

Review 10.  APP transgenic modeling of Alzheimer's disease: mechanisms of neurodegeneration and aberrant neurogenesis.

Authors:  Leslie Crews; Edward Rockenstein; Eliezer Masliah
Journal:  Brain Struct Funct       Date:  2009-11-29       Impact factor: 3.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.